The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.

"Declarations Ethics approval and consent to participateThis research was approved by the Hadassah-Hebrew University Medical Center Institutional Review Board (IRB) (0259–19-HMO) and the Kaplan Medical Center ethics committee (KMC-0036-10). Due to the retrospective design of the research, a waiver of informed consent of the participants in the study was provided by both ethics committees. Consent for publicationNot applicable. Due to the retrospective design of the research, and the usage of anonymized data, a waiver of informed consent of the participants was approved by the both institutions ethics committees, thus approval for publication by the participants is not requested as well. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding Dr. Maman is the first author, and the work was part of the requirements of the Hebrew University for a medical doctor degree. The study was not funded by any grant, organization, or company."